Global Central Nervous System Biomarkers Market 2023-2029

March 2023 | 72 pages | ID: G790DADC1BADEN
Gen Consulting Company

Abstracts

Central Nervous System (CNS) biomarkers are biological indicators that can be measured in blood, cerebrospinal fluid or brain tissue to provide information about the function and structure of the central nervous system. Such biomarkers have been increasingly used in clinical research and diagnosis of various neurological disorders characterized by damage to the CNS, such as Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, and traumatic brain injury, and aid in understanding disease progression or identifying potential therapeutic targets. The global central nervous system biomarkers market is expected to increase by USD 3.2 billion, at a compound annual growth rate (CAGR) of 8.48% from 2023 to 2029, according to the latest edition of the Global Central Nervous System Biomarkers Market Report.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global central nervous system biomarkers market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the type of CNS biomarker, application, end user, and region. The global market for central nervous system biomarkers can be segmented by type of CNS biomarker: safety biomarker, efficacy biomarker, validation biomarker, others. The safety biomarker segment is estimated to account for the largest share of the global central nervous system biomarkers market. Central nervous system biomarkers market is further segmented by application: drug discovery and development, personalized medicine, others. The drug discovery and development segment held the largest revenue share in 2022. Based on end user, the central nervous system biomarkers market is segmented into: diagnostic laboratories, clinics/hospitals, research centers. Globally, the research centers segment made up the largest share of the central nervous system biomarkers market. On the basis of region, the central nervous system biomarkers market also can be divided into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. North America was the largest contributor to the global central nervous system biomarkers market in 2022.

Market Segmentation
By type of CNS biomarker: safety biomarker, efficacy biomarker, validation biomarker, others
By application: drug discovery and development, personalized medicine, others
By end user: diagnostic laboratories, clinics/hospitals, research centers
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America

The market research report covers the analysis of key stake holders of the global central nervous system biomarkers market. Some of the leading players profiled in the report include Merck KGaA, Eli Lilly and Company, Bio-Rad Laboratories Inc., bioM?rieux SA, Thermo Fisher Scientific Inc., Acumen Pharmaceuticals, Inc., Alseres Pharmaceuticals Inc., Proteome Sciences plc, Enzo Biochem Inc., H.U. Group Holdings Inc., among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Scope of the Report
To analyze and forecast the market size of the global central nervous system biomarkers market.
To classify and forecast the global central nervous system biomarkers market based on type of CNS biomarker, application, end user, region.
To identify drivers and challenges for the global central nervous system biomarkers market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global central nervous system biomarkers market.
To identify and analyze the profile of leading players operating in the global central nervous system biomarkers market.

Why Choose This Report
Gain a reliable outlook of the global central nervous system biomarkers market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints

PART 5. MARKET BREAKDOWN BY TYPE OF CNS BIOMARKER

Safety biomarker
Efficacy biomarker
Validation biomarker
Others

PART 6. MARKET BREAKDOWN BY APPLICATION

Drug discovery and development
Personalized medicine
Others

PART 7. MARKET BREAKDOWN BY END USER

Diagnostic laboratories
Clinics/hospitals
Research centers

PART 8. MARKET BREAKDOWN BY REGION

North America
Europe
Asia-Pacific
MEA (Middle East and Africa)
Latin America

PART 9. KEY COMPANIES

Merck KGaA
Eli Lilly and Company
Bio-Rad Laboratories Inc.
bioM?rieux SA
Thermo Fisher Scientific Inc.
Acumen Pharmaceuticals, Inc.
Alseres Pharmaceuticals Inc.
Proteome Sciences plc
Enzo Biochem Inc.
H.U. Group Holdings Inc.

DISCLAIMER